Lisa G Rider Selected Research

Dermatomyositis (Dermatopolymyositis)

1/2022	Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis.
1/2022	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis.
1/2022	Conflicting reports of anti-cytosolic 5'-nucleotidase 1A autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld et al.
1/2022	Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses.
1/2022	Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.
10/2021	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis.
1/2021	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
1/2021	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
1/2021	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.
6/2020	Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lisa G Rider Research Topics

Disease

58	Myositis (Idiopathic Inflammatory Myopathies) 06/2022 - 07/2002
44	Dermatomyositis (Dermatopolymyositis) 01/2022 - 07/2002
10	Polymyositis 01/2019 - 11/2005
8	Autoimmune Diseases (Autoimmune Disease) 06/2022 - 09/2003
7	Calcinosis 06/2020 - 12/2008
6	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 07/2013
4	Inflammation (Inflammations) 06/2020 - 03/2012
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2022 - 03/2014
3	Infections 04/2022 - 03/2016
3	Rheumatic Diseases (Rheumatism) 01/2022 - 07/2018
3	Inclusion Body Myositis 11/2017 - 11/2005
2	Systemic Scleroderma (Systemic Sclerosis) 06/2022 - 09/2003
2	Deglutition Disorders (Dysphagia) 01/2022 - 10/2021
2	COVID-19 01/2022 - 01/2021
2	Arthritis (Polyarthritis) 01/2021 - 11/2020
2	Arthralgia (Joint Pain) 01/2021 - 07/2013
2	Dysphonia (Spastic Dysphonia) 01/2021 - 07/2013
2	Melanoma (Melanoma, Malignant) 01/2021 - 11/2018
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2019 - 11/2006
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 07/2018 - 01/2018
2	Muscular Atrophy (Muscle Atrophy) 12/2013 - 11/2009
2	Exanthema (Rash) 07/2013 - 11/2006
2	Neoplasms (Cancer) 11/2006 - 11/2005
1	Klinefelter Syndrome (Klinefelter's Syndrome) 06/2022
1	Thrombocytopenia (Thrombopenia) 04/2022
1	Fatty Liver 04/2022
1	Liver Diseases (Liver Disease) 04/2022
1	Portal Hypertension 04/2022
1	Gastroenteritis 04/2022
1	Ulcer 01/2022
1	Crohn Disease (Crohn's Disease) 01/2022
1	Cardiomyopathies (Cardiomyopathy) 10/2021
1	Lymphadenopathy 01/2021
1	Rheumatoid Arthritis 01/2021
1	Contracture 01/2021
1	Infarction (Infarctions) 01/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Ischemia 06/2020
1	Wounds and Injuries (Trauma) 06/2020
1	Pulmonary Alveolar Proteinosis 01/2020
1	Bites and Stings (Sting) 01/2020
1	Macrophage Activation Syndrome 01/2020
1	Lung Diseases (Lung Disease) 11/2017

Drug/Important Bio-Agent (IBA)

40	AutoantibodiesIBA 04/2022 - 07/2002
7	Rituximab (Mabthera)FDA Link 05/2017 - 02/2013
6	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 04/2010
6	Mi-2 antibodiesIBA 01/2022 - 07/2002
5	AntibodiesIBA 01/2022 - 02/2006
5	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2022 - 01/2006
4	Biological ProductsIBA 01/2022 - 01/2015
4	EnzymesIBA 01/2022 - 10/2002
3	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2022 - 03/2012
3	VaccinesIBA 01/2022 - 01/2017
3	Interferon Type IIBA 10/2020 - 09/2010
3	Biomarkers (Surrogate Marker)IBA 06/2020 - 01/2016
3	sodium thiosulfate FDA Link 01/2020 - 03/2012
3	Ligases (Synthetase)IBA 01/2019 - 11/2006
3	CytokinesIBA 03/2014 - 12/2008
3	Signal Recognition ParticleIBA 03/2014 - 11/2006
2	Complement System Proteins (Complement)IBA 06/2022 - 01/2016
2	InterferonsIBA 06/2022 - 01/2020
2	5'-Nucleotidase (5' Nucleotidase)IBA 01/2022 - 01/2018
2	Antirheumatic Agents (DMARD)IBA 01/2021 - 11/2020
2	transcriptional intermediary factor 1IBA 01/2021 - 11/2018
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2017 - 01/2017
2	Prednisone (Sone)FDA LinkGeneric 05/2017 - 01/2017
2	Methotrexate (Mexate)FDA LinkGeneric 05/2017 - 01/2017
2	Peptides (Polypeptides)IBA 12/2006 - 11/2005
2	HLA-A Antigens (HLA-A)IBA 03/2006 - 11/2005
1	Transaminases (Aminotransferases)IBA 04/2022
1	FlagellinIBA 01/2022
1	ImmunosorbentsIBA 01/2022
1	CortactinIBA 01/2022
1	Prostaglandins AIBA 01/2022
1	GlucocorticoidsIBA 10/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 10/2021
1	nuclear matrix protein 2IBA 01/2021
1	baricitinibIBA 01/2021
1	IFIH1 Interferon-Induced HelicaseIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Janus KinasesIBA 01/2021
1	ProteomeIBA 10/2020
1	Phosphates (Orthophosphate)IBA 06/2020
1	CalciumIBA 06/2020
1	SaltsIBA 06/2020
1	Interleukin-18 (Interleukin 18)IBA 01/2020
1	tofacitinibIBA 11/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	SS-A antibodiesIBA 01/2019
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2019
1	Pharmaceutical PreparationsIBA 07/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017
1	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 01/2017
1	Oxidoreductases (Dehydrogenase)IBA 01/2017
1	Complement C4 (Complement Component 4)IBA 01/2016

Therapy/Procedure

16	Therapeutics 07/2018 - 11/2002
2	Gas Lasers 01/2020 - 11/2019
2	Aftercare (After-Treatment) 03/2016 - 01/2009
1	Self-Help Devices (Assistive Technology) 01/2022
1	Polypharmacy 11/2017